Fundraising Fox
Lyterian Therapeutics
South San Francisco, US · Founded 2022 · 27 employees on LinkedIn · 1 known investors
Find your way into Lyterian Therapeutics
Sign up to see every warm intro you have to Lyterian Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Lyterian Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Lyterian Therapeutics develops pharmaceutical treatments by leveraging protein homeostatic mechanisms to target genetically-validated disease drivers. The company focuses on transformative medicines for patients across multiple disease areas.
Investors · 1
The Column Grouplisted by The Column GroupSan Francisco · $30M
How we know: The Column Group's portfolio page · the VCSheet dataset · Not right? Tell us
Frequently asked questions
- What does Lyterian Therapeutics do?
- Lyterian Therapeutics develops pharmaceutical treatments by leveraging protein homeostatic mechanisms to target genetically-validated disease drivers. The company focuses on transformative medicines for patients across multiple disease areas.
- Who are Lyterian Therapeutics's investors?
- Lyterian Therapeutics's investors include The Column Group.
- Where is Lyterian Therapeutics headquartered?
- Lyterian Therapeutics is headquartered in South San Francisco, US.